Researchers have identified a potential therapeutic option for long COVID sufferers experiencing debilitating fatigue. A randomized clinical trial encompassing 399 adults found that fluvoxamine, an inexpensive antidepressant medication, substantially lessened fatigue symptoms and enhanced overall quality of life compared to placebo treatment.
The findings represent a significant development in addressing long COVID, a condition that has affected millions worldwide with persistent and often severe fatigue. Fluvoxamine emerges as among the first pharmacological interventions to demonstrate clinically meaningful improvements for patients dealing with this challenging post-viral syndrome.
More Stories
Family of Air Force Veteran Holds Cooling Tower Owner Responsible in UES Legionnaires’ Disease Death
CDC Investigates Third Gastrointestinal Outbreak on Alaska Expedition Vessel in Eight Weeks
Immune Cells, Not Brain Plaques, Drive Sleep Loss in Alzheimer’s, Study Finds